

Giuseppe Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/623043/publications.pdf>

Version: 2024-02-01

64
papers

2,800
citations

279701

23
h-index

182361

51
g-index

67
all docs

67
docs citations

67
times ranked

4271
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 509-514.	3.9	661
2	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. <i>Nature Metabolism</i> , 2021, 3, 774-785.	5.1	259
3	The inflammatory status score including IL-6, TNF- α , osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2014, 51, 123-131.	1.2	211
4	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2036-2041.	4.3	155
5	Dapagliflozin Lowers Plasma Glucose Concentration and Improves β -Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1927-1932.	1.8	133
6	Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. <i>Diabetes Care</i> , 2015, 38, 1509-1517.	4.3	99
7	Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. <i>Diabetologia</i> , 2012, 55, 1847-1855.	2.9	95
8	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. <i>Hepatology</i> , 2016, 64, 2028-2037.	3.6	78
9	Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3/TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. <i>Diabetologia</i> , 2013, 56, 2153-2163.	2.9	71
10	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 1999-2006.	0.3	67
11	Empagliflozin Treatment Is Associated With Improved β -Cell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1402-1407.	1.8	63
12	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 809-813.	2.2	61
13	Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals. <i>Diabetes</i> , 2014, 63, 2812-2820.	0.3	60
14	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 651-660.	1.8	51
15	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. <i>Diabetes</i> , 2015, 64, 3406-3412.	0.3	45
16	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2019, 18, 159.	2.7	43
17	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. <i>Diabetologia</i> , 2017, 60, 1102-1113.	2.9	38
18	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. <i>Current Pharmaceutical Design</i> , 2013, 19, 2420-2431.	0.9	37

#	ARTICLE	IF	CITATIONS
19	Metabolic regulation of GLP-1 and PC1/3 in pancreatic β -cell line. PLoS ONE, 2017, 12, e0187836.	1.1	31
20	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1249-1256.	1.8	30
21	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care, 2009, 32, S342-S348.	4.3	27
22	Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. FEBS Journal, 2017, 284, 451-465.	2.2	27
23	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. Internal and Emergency Medicine, 2008, 3, 87-98.	1.0	25
24	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs, 2017, 77, 247-264.	4.9	25
25	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. Metabolism: Clinical and Experimental, 2021, 114, 154416.	1.5	23
26	The metabolic syndrome is related to albuminuria in Type 2 diabetes. Diabetic Medicine, 2008, 25, 1412-1418.	1.2	22
27	What are the pharmacotherapy options for treating prediabetes?. Expert Opinion on Pharmacotherapy, 2014, 15, 2003-2018.	0.9	21
28	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β -Cell Function in Subjects With Impaired Fasting Glucose. Diabetes, 2017, 66, 2495-2502.	0.3	21
29	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 162, 108112.	1.1	21
30	Altered Visual Plasticity in Morbidly Obese Subjects. IScience, 2019, 22, 206-213.	1.9	20
31	The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine, 2015, 50, 568-574.	1.1	19
32	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. Diabetologia, 2020, 63, 2423-2433.	2.9	17
33	Effects of Intermittent Fasting on Brain Metabolism. Nutrients, 2022, 14, 1275.	1.7	17
34	Access to emergency room for hypoglycaemia in people with diabetes. Diabetes/Metabolism Research and Reviews, 2015, 31, 745-751.	1.7	15
35	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1160-E1167.	1.8	15
36	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetologica, 2015, 52, 1129-1133.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. <i>Diabetes Care</i> , 2016, 39, 1804-1810.	4.3	15
38	Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 648-657.	2.2	15
39	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	4.3	15
40	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , 2019, 4, .	2.3	15
41	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 550-557.	1.2	14
42	The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. <i>Acta Diabetologica</i> , 2018, 55, 139-148.	1.2	14
43	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> , 2020, 43, e139-e141.	4.3	13
44	Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge. <i>Frontiers in Endocrinology</i> , 2020, 11, 10.	1.5	11
45	Brain effect of bariatric surgery in people with obesity. <i>International Journal of Obesity</i> , 2022, 46, 1671-1677.	1.6	11
46	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 216.	1.5	10
47	Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 181-186.	1.7	5
48	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018, 17, 78.	2.7	5
49	Plasma N-acetylaspartate: Development and validation of a quantitative assay based on HPLC-MS-MS and sample derivatization. <i>Clinica Chimica Acta</i> , 2020, 508, 146-153.	0.5	5
50	Circulating N-Acetylaspartate does not track brain NAA concentrations, cognitive function or features of small vessel disease in humans. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
51	Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. <i>International Journal of Obesity</i> , 2021, 45, 1821-1829.	1.6	4
52	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 2287-2287.	3.9	4
53	Insulin secretion and action affect glucose variability in the early stages of glucose intolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3531.	1.7	4
54	Fiber orientation measurements by diffusion tensor imaging improve hydrogen-1 magnetic resonance spectroscopy of intramyocellular lipids in human leg muscles. <i>Journal of Medical Imaging</i> , 2015, 2, 026002.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Exenatide modulates visual cortex responses. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3167.	1.7	3
56	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. <i>Diabetologia</i> , 2017, 60, 2123-2125.	2.9	2
57	Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 699477.	1.2	2
58	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report. <i>Frontiers in Endocrinology</i> , 2022, 13, 847778.	1.5	2
59	Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2015, 52, 897-903.	1.2	1
60	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> 2020;43:e139â€“e141. <i>Diabetes Care</i> , 2021, 44, e81-e81.	4.3	1
61	Prognostic implications of diabetes phenotyping: new concepts for an old disease. <i>Internal and Emergency Medicine</i> , 2009, 4, 325-329.	1.0	0
62	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
63	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
64	LA MALATTIA RENALE CRONICA NON-ALBUMINURICA NEL DIABETE MELLITO TIPO 1. <i>Il Diabete</i> , 2019, 31, .	0.0	0